|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Ms E Walmsley
|
|
|
b)
|
Position/status
|
Chief
Executive Officer
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 11 January 2018 on Ordinary
Shares held in the Company's 2009 Deferred Annual Bonus
Plan.
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£13.306
|
87.861
|
||
|
£13.306
|
87.861
|
||
|
£13.306
|
217.580
|
||
|
£13.306
|
217.564
|
||
|
£13.306
|
236.894
|
||
|
£13.306
|
236.879
|
||
|
d)
|
Aggregated
information
Aggregated
volume Price
|
1,084.639
£13.306
|
|
|
e)
|
Date
of the transaction
|
2018-01-11
|
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Mr R G Connor
|
|
|
b)
|
Position/status
|
President, Global Manufacturing & Supply
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 11 January 2018 on Ordinary
Shares held in the Company's 2009 Deferred Annual Bonus
Plan.
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£13.306
|
64.344
|
||
|
£13.306
|
64.344
|
||
|
£13.306
|
147.828
|
||
|
£13.306
|
123.348
|
||
|
£13.306
|
123.334
|
||
|
d)
|
Aggregated
information
Aggregated
volume Price
|
523.198
£13.306
|
|
|
e)
|
Date
of the transaction
|
2018-01-11
|
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Mr L Debruyne
|
|
|
b)
|
Position/status
|
President, Global Vaccines
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 11 January 2018 on Ordinary
Shares held in the Company's 2009 Deferred Annual Bonus
Plan.
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£13.306
|
207.321
|
||
|
£13.306
|
207.306
|
||
|
d)
|
Aggregated
information
Aggregated
volume Price
|
414.627
£13.306
|
|
|
e)
|
Date
of the transaction
|
2018-01-11
|
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Mr S Dingemans
|
|
|
b)
|
Position/status
|
Chief Financial Officer
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 11 January 2018 on Ordinary
Shares held in the Company's 2009 Deferred Annual Bonus
Plan.
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£13.306
|
122.724
|
||
|
£13.306
|
122.707
|
||
|
£13.306
|
287.332
|
||
|
£13.306
|
287.316
|
||
|
£13.306
|
215.211
|
||
|
£13.306
|
215.211
|
||
|
d)
|
Aggregated
information
Aggregated
volume Price
|
1,250.501
£13.306
|
|
|
e)
|
Date
of the transaction
|
2018-01-11
|
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Mr N Hirons
|
|
|
b)
|
Position/status
|
SVP, Global Ethics & Compliance
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 11 January 2018 on Ordinary
Shares held in the Company's 2009 Deferred Annual Bonus
Plan.
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£13.306
|
45.052
|
||
|
£13.306
|
45.052
|
||
|
£13.306
|
106.239
|
||
|
£13.306
|
106.239
|
||
|
£13.306
|
77.966
|
||
|
£13.306
|
77.951
|
||
|
d)
|
Aggregated
information
Aggregated
volume Price
|
458.499
£13.306
|
|
|
e)
|
Date
of the transaction
|
2018-01-11
|
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Mr B McNamara
|
|
|
b)
|
Position/status
|
CEO, GSK Consumer Healthcare
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN:
US37733W1053
|
|
|
b)
|
Nature
of the transaction
|
Acquisition of ADSs following the re-investment of dividends paid
to shareholders on 11 January 2018 on ADSs held in the Company's
2009 Deferred Annual Bonus Plan.
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
$36.84
|
87.876
|
||
|
d)
|
Aggregated
information
Aggregated
volume Price
|
87.876
$36.84
|
|
|
e)
|
Date
of the transaction
|
2018-01-11
|
|
|
f)
|
Place
of the transaction
|
New York Stock Exchange (XNYS)
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Mr D S Redfern
|
|
|
b)
|
Position/status
|
Chief Strategy Officer
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 11 January 2018 on Ordinary
Shares held in the Company's 2009 Deferred Annual Bonus
Plan.
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£13.306
|
72.194
|
||
|
£13.306
|
72.194
|
||
|
£13.306
|
135.207
|
||
|
£13.306
|
135.207
|
||
|
£13.306
|
98.121
|
||
|
£13.306
|
98.106
|
||
|
d)
|
Aggregated
information
Aggregated
volume Price
|
611.029
£13.306
|
|
|
e)
|
Date
of the transaction
|
2018-01-11
|
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Ms C Thomas
|
|
|
b)
|
Position/status
|
SVP, Human Resources
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 11 January 2018 on Ordinary
Shares held in the Company's 2009 Deferred Annual Bonus
Plan.
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£13.306
|
97.174
|
||
|
£13.306
|
97.158
|
||
|
£13.306
|
197.805
|
||
|
£13.306
|
197.805
|
||
|
£13.306
|
147.686
|
||
|
£13.306
|
147.686
|
||
|
d)
|
Aggregated
information
Aggregated
volume Price
|
885.314
£13.306
|
|
|
e)
|
Date
of the transaction
|
2018-01-11
|
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Mr P C Thomson
|
|
|
b)
|
Position/status
|
President, Global Affairs
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 11 January 2018 on Ordinary
Shares held in the Company's 2009 Deferred Annual Bonus
Plan.
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£13.306
|
66.002
|
||
|
£13.306
|
121.024
|
||
|
£13.306
|
92.975
|
||
|
d)
|
Aggregated
information
Aggregated
volume Price
|
280.001
£13.306
|
|
|
e)
|
Date
of the transaction
|
2018-01-11
|
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Mr D E Troy
|
|
|
b)
|
Position/status
|
SVP & General Counsel
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W1053
|
|
|
b)
|
Nature
of the transaction
|
Acquisition of ADSs following the re-investment of dividends paid
to shareholders on 11 January 2018 on ADSs held in the Company's
2009 Deferred Annual Bonus Plan.
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
$36.84
|
50.006
|
||
|
$36.84
|
50.006
|
||
|
$36.84
|
112.593
|
||
|
$36.84
|
112.593
|
||
|
$36.84
|
93.253
|
||
|
$36.84
|
93.239
|
||
|
d)
|
Aggregated
information
Aggregated
volume Price
|
511.690
$36.84
|
|
|
e)
|
Date
of the transaction
|
2018-01-11
|
|
|
f)
|
Place
of the transaction
|
New York Stock Exchange (XNYS)
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Dr P J T Vallance
|
|
|
b)
|
Position/status
|
President,
R&D
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 11 January 2018 on Ordinary
Shares held in the Company's 2009 Deferred Annual Bonus
Plan.
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£13.306
|
143.039
|
||
|
£13.306
|
143.039
|
||
|
£13.306
|
232.681
|
||
|
£13.306
|
232.681
|
||
|
£13.306
|
160.411
|
||
|
£13.306
|
160.411
|
||
|
d)
|
Aggregated
information
Aggregated
volume Price
|
1,072.262
£13.306
|
|
|
e)
|
Date
of the transaction
|
2018-01-11
|
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
|
|
GlaxoSmithKline plc
|
|
|
(Registrant)
|
|
|
|
|
Date: January
16, 2018
|
|
|
|
|
|
|
By: VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GlaxoSmithKline plc
|